Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.
Semaglutide, best known for its role in metabolic research, is now showing potential in behavioral studies. Researchers at Virginia Commonwealth University ran a simple but telling experiment: give rats a choice between cocaine and food, then see what changes when you introduce repeated semaglutide treatment. The results are hard to ignore. Over five days, both male and female rats treated with semaglutide picked cocaine less often and even dropped some body weight.
Neuropsychopharmacology
by Heslep N, Marsh SA, Banks ML
“Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats. Heslep N(1), Marsh SA(1), Banks ML(2). Author information: (1)Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. (2)Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. Mbanks7@vcu.edu. The present study determined the effectiveness of the glucagon-like peptide 1 agonist semaglutide to attenuate cocaine-vs-food choice in male and female rats. Repeated 5-day semaglutide treatment decreased cocaine choice and significantly reduced body weight. These preclinical results support the clinical evaluation of semaglutide as a candidate cocaine use disorder medication. © 2026. The Author(s). Conflict of interest statement: Competing interests: All authors declare that no actual or perceived conflicts of interest exist.”
Key takeaway: semaglutide isn’t just about glucose and appetite anymore. Now it’s making waves in preclinical models of substance preference.
Why does this matter for peptide researchers?
Semaglutide is a GLP-1 agonist. Its primary buzz has been in diabetes and obesity studies, but this research points to broader neurobehavioral effects.
The reduction in cocaine choice suggests semaglutide could influence the brain’s reward system, not just metabolic signaling.
Both sexes responded, which is crucial for future research design.
The study stops well short of human claims, but this data gives the go-ahead for clinical research into semaglutide for cocaine use disorder. For anyone in the peptide field, this means new grant angles, new collaborations, and more reasons to keep an eye on this versatile compound.
If you’re sourcing peptides for similar behavioral studies or looking to replicate this work, check the semaglutide page for more background. Researchers looking for reputable suppliers can browse the vendor directory to compare options for quality and availability.
As more labs pivot toward multi-purpose peptide research, semaglutide is proving it’s not just a one-trick pony.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.